Sulfation of α-hydroxytamoxifen catalyzed by human hydroxysteroid sulfotransferase results in tamoxifen-DNA adducts

Carcinogenesis

Volumn 19, Issue 11, 1998, Pages 2007-2011

  Shibutani, Shinya ^a   Shaw, Peter M ^b   Suzuki, Naomi ^a   Dasaradhi, Lakkaraju ^a   Duffel, Michael W ^c   Terashima, Isamu ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b INVITROGEN CORPORATION   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE 3' PHOSPHATE 5' PHOSPHOSULFATE; DNA; HYDROXYTAMOXIFEN; PHOSPHORUS 32; RECOMBINANT ENZYME; SULFOTRANSFERASE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA ADDUCT; DRUG DNA INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; STEREOISOMERISM; SULFATION;

ANIMALS; DNA ADDUCTS; ESTROGEN ANTAGONISTS; HUMANS; SPODOPTERA; SULFATES; SULFOTRANSFERASES; TAMOXIFEN;

EID: 0031721571     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Jordan, V.C. (1993) A current view of tamoxifen for the treatment and prevention of breast cancer. Br. J. Pharmacol., 110, 507-517.
2. Powles, T.J., Hardy, J.R., Ashley, S.E. et al. (1993) A pilot trial to evaluate the acute toxicology and feasibility of tamoxifen for the prevention of breast cancer. Br. J. Cancer, 60, 126-131.
3. Nayfield, S.G., Karp, J.E., Ford, L.G., Dorr, F.A. and Kramer, B.S. (1991) Potential role of tamoxifen in prevention of breast cancer. J. Natl Cancer Inst., 83, 1450-1459.
4. Williams, G.M., Iatropoulos, M.J., Djordjevic, M.V. and Kaltenberg, O.P. (1993) The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis, 14, 315-317.
5. Greaves, P., Goonetilleke, R., Nunn, G., Topham, J. and Orton, T. (1993) Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res., 53, 3919-3924.
6. Hard, G.C., Iatropoulos, M.J., Jordan, K., Radi, L., Kaltenberg, O.P., Imondi, A.R. and Williams, G.M. (1993) Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD (BR) rats. Cancer Res., 53, 4534-4541.
7. Davies, R., Oreffo, V.I.C., Martin, E.A., Festing, M.F.W., White, I.N.H., Smith, L.L. and Styles, J.A. (1997) Tamoxifen causes gene mutations in the livers of lambda/lacI transgenic rats. Cancer Res., 57, 1288-1293.
8. Seoud, M.A.-F., Johnson, J. and Weed, J.C. (1993) Gynecological tumors in tamoxifen-treated women with breast cancer. Obstet. Gynecol., 82, 165-169.
9. Fischer, B., Costantino, J.P, Redmond, C.K., Fisher, E.R., Wickerham, D.L. and Cronin, W.M. (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl Cancer Inst., 86, 527-537.
10. van Leeuwen, F.E., Benraadt, J., Coebergh, J.W.W., Kiemeney, L.A.L.M., Diepenhorst, F.W., van den Belt-Dusebout, A.W. and van Tinteren, H. (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet, 343, 448-452.
11. IARC (1996) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 66. Some Pharmaceutical Drugs. IARC Scientific Publications, IARC, Lyon.
12. Han, X. and Liehr, J.G. (1992) Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res., 52, 1360-1363.
13. White, I.N.H., de Matteis, F., Davies, A., Smith, L.L., Crofton-Sleigh, C., Venitt, S., Hewer, A. and Phillips, D.H. (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57B1/6 mice and in human MCL-5 cells. Carcinogenesis, 13, 2197-2203.
14. Moorthy, B., Sriram, P., Pathak, D.N., Bodell, W.J. and Randerath, K. (1992) Tamoxifen metabolic activation: comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vitro. Cancer Res., 56, 53-57.
15. Dasaradhi, L. and Shibutani, S. (1997) Identification of tamoxifen-DNA adducts formed by α-sulfate tamoxifen and α-acetoxytamoxifen. Chem. Res. Toxicol., 10, 189-196.
16. Osborne, M.R., Hewer, A., Hardcastle, I.R., Carmichael, P.L. and Phillips, D.H. (1996) Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res., 56, 66-71.
17. 2-deoxyguanosinyl)tamoxifen. Biochemistry, 36, 13010-13017.
18. Shibutani, S., Dasaradhi, L., Terashima, I., Banoglu, E. and Duffel, M.W. (1998) α-Hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen-DNA adducts. Cancer Res., 58, 647-653.
19. Glatt, H., Pauly, K., Czich, A., Falany, J.L. and Falany, C.N. (1995) Activation of benzylic alcohols to mutagens by rat and human sulfotransferases expressed in Escherichia coli. Eur. J. Pharmacol., 293, 173-181.
20. 5. Arch. Biochem. Biophys, 348, 107-115.
21. Chen, G., Banoglu, E. and Duffel, M.W. (1996) Influence of substrate structure on the catalytic efficiency of hydroxysteroid sulfotransferase STa in the sulfation of alcohols. Chem. Res. Toxicol., 9, 67-74.
22. Foster, A.B., Jarman, M., Leung, O-T., McCague, R., Leclercq, G. and Devleeschouwer, N. (1985) Hydroxy derivatives of tamoxifen. J. Med. Chem., 28, 1491-1497.
23. 32P-postlabeling. Carcinogenesis, 12, 1181-1186.
24. Maniatis, T., Fritsch, E.F. and Sambrook, J. (1982) Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
25. Phillips, D.H., Carmichael, P.L., Hewer, A., Cole, K.J. and Poon, G.K. (1994) α-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res., 54, 5518-5522.
26. 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis, 15, 2087-2094.
27. Phillips, D.H., Carmichael, P.L., Hewer, A., Cole, K.I., Hardcastle, I.R., Poon, G.K., Keogh, A. and Strain, A.J. (1996) Activation of tamoxifen and its metabolite α-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes. Carcinogenesis, 17, 89-94.
28. Phillips, D.H., Hewer, A., Grover, P.L., Poon, G.K. and Carmichael, P.L. (1996) Tamoxifen does not form detectable adducts in white blood cells of breast cancer patients. Carcinogenesis, 17, 1149-1152.
29. Carmichael, P.L., Ugwumadu, A.H.N., Neven, P. Hewer, A.J., Poon, G.K. and Phillips, D.H. (1996) Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res., 56, 1475-1479.
30. Hemminki, K., Rajaniemi, H., Koskinen, M. and Hansson, J. (1997) Tamoxifen-induced DNA adducts in leucocytes of breast cancer patients. Carcinogenesis, 18, 9-13.
31. Hemminki, K., Rajaniemi, H., Lindahl, B. and Moberger, B. (1996) Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res., 56, 4374-1377.
32. Orton, T.C., Topham, J.C. and Park, A. (1997) Correspondence re: K. Hemminki et al., tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res., 57, 4148.